Making Longevity Mainstream

In 2026, the “quantified self” is growing rapidly.

Wearables, blood tests, AI-enabled beds. Increasingly, the urban upper-middle class are seeking knobs to optimize and goals to meet. Whoop and Oura, using social status as a lever, have hit 7.5 million total subscribers. Function Health and Superpower are reaching unicorn valuations selling annual blood tests. Premium diagnostic services like Neko have conducted over 100,000 scans.

Hidden within a small sect of the emerging health-data frenzy is the longevity movement; individuals who use said data for interventions beyond the typical “increase in daily step count” or “sleeping on time.” Think peptides, red light therapy, and far-out sci-fi tech like cryopreservation. These people are inventing a new, fully private healthcare ecosystem around living forever.

The casual health data enthusiast and aspiring immortal are both high-class; they have excess time to spend on optimization and access to a high-quality base level of primary care. As a result, the massive product ecosystem to support this demographic is positioned largely as luxury, with sleek design language, status signaling, and high-costs that make the value proposition for the average American difficult. If private healthcare continues to cater to the 1%, health becomes a social hierarchy only climbable by the wealthy.

Human longevity as a societal movement will fail if this is the case.

We should dream of a future where all are free to optimize for long, healthy lives without worrying about luxury price tags. Preventative healthcare should be ubiquitously seen as an essential component of modern life, rather than an artifact of the high-end consumer health market. Incredible strides in medical technology have lowered costs and raised care standards all over the world, but more work is to be done.

Here’s how we’re doing our part to make longevity for everyone.

Physical Bottlenecks in Medicine

In general, behavior within healthcare will follow incentives. Cost, time, and accessibility all affect these incentives; a patient is much less likely to get their pain checked out if the costs are high, it takes too long, or it is too much effort. For cash-pay preventative healthcare, there are 3 main physical layers that dictate patient behavior:

Intelligence to onboard and manage patients (analogous to primary care) → diagnostics layer for clinical decisions → intervention layer for treatment

The intelligence layer is changing fast. Given the rise of AI from frontier labs like OpenAI and specialized labs like OpenEvidence, knowledge work in medicine is becoming too cheap to meter. The slice of primary care done by humans will shrink exponentially, until all non-physical evaluation and management tasks can be digitally automated. Very soon, intelligence will no longer be a bottleneck.

Interventions are a tougher task because they vary wildly in difficulty. Sometimes (especially with preventative healthcare), being more active and eating healthier are all that’s necessary, while other times a surgeon is required. The portion of interventions that are significantly improvable in telemedicine are very small and are mostly dependent on pharma; GLP-1s are a great example.

Diagnostics, it seems, should be the hardest of them all; the service layer has remained unchanged for 40 years, relying on the exact same technology with the same limitations. Doing a blood test in 2026 requires vials upon vials of blood drawn at a clinic, shipped off to a lab, and days of delay. Critically, if the patient is most concerned about meeting their health goals, the intelligence and diagnostics layer become secondary to the intervention; the biggest barrier in the way of patient care becomes these hardware limitations.

Fixing diagnostic infrastructure will let the patient flywheel spin significantly faster. As costs drop and delays erode, the incentives barring most Americans from meeting their health goals will subside.

This problem is now the most effective way forward for the future of health.

What does the path forward look like?

There are so many brilliant companies bringing new ideas and technologies to the table. Any one of them could change the world in a number of ways; VitalBio and SiPhox are miniaturizing testing, Roche and Ultima Genomics continue to lower the price of whole-genome sequencing, and plenty of startups are trying (and are having early success with) continuous hormone monitoring. None of these are incorrect, as each has their own unlocks and market potential, but we see a clear, elegant path to lower costs and lower wait times.

You might remember using a COVID-19 rapid test from a few years ago. Almost overnight, this obscure test confined to academic labs became manufacturable on the order of 100s of millions per month. Billions poured into R&D, and government policy incentivized massive scaleups. 6 years later, this test, called a lateral flow assay, has tremendously expanded capability. Readings are now quantitative, at sensitivities and precision equivalent to lab tests, with a bill of materials that costs less than a KitKat. Both academia and the private sector have developed gold-standard tests in this format for a wide variety of analytes; what’s missing is a unified platform that centralizes the readings and makes for a great user experience.

Matrix is making this platform. We want any person in America to walk into a Walgreens and have immediate access to whatever marker panels they desire, at a price they can afford. The lateral flow assay technology that exists today is already accurate, widely used, and commercially viable; using LFA, Matrix eliminates the blood draw, the third party lab, and the days of delay, making testing economics an order of magnitude better with a better patient experience. The foundation is here, it is simply a matter of scaling and execution.

Getting this right means better diagnostics for billions of people. No longer will biochemical data be an expensive obstacle in the way of interventions; patients will be free to test at whatever frequency they wish, right in their homes.

Longevity as a concept doesn’t need to be gated to the 1%. Better blood testing means everyone can have the tools to live long, healthy lives — regardless of class, status, or background.